MoonLake Immunotherapeutics Aktie

33,23 USD -1,74 USD -4,98 %

19:34:37

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.2,01 Mrd. EUR

Div. Rendite0,00%

WKNA3DFA7

ISINKY61559X1045

SymbolMLTX

MoonLake Immunotherapeutics Aktien News

Sortieren:Datum Meistgelesen

03.04.25GlobeNewswireMoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

26.02.25GlobeNewswireMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

08.01.25GlobeNewswireMoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

13.11.24GlobeNewswireMoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

07.11.24GlobeNewswireMoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

09.09.24GlobeNewswireMoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

07.08.24GlobeNewswireMoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

10.06.24GlobeNewswireMoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

16.05.24GlobeNewswireMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

10.03.24GlobeNewswireMoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

04.03.24GlobeNewswireMoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

29.02.24GlobeNewswireMoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

26.02.24GlobeNewswireMoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

14.11.23GlobeNewswireMoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

05.11.23GlobeNewswireMoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

15.10.23GlobeNewswireMoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hi

11.10.23GlobeNewswireMoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Co

06.09.23GlobeNewswireMoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

10.08.23GlobeNewswireMoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

25.07.23GlobeNewswireMoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

28.06.23GlobeNewswireMoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

26.06.23GlobeNewswireMoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

25.06.23GlobeNewswireMoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

12.05.23GlobeNewswireMoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

03.05.23GlobeNewswireMoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

19.04.23GlobeNewswireMoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

20.03.23GlobeNewswireMoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

14.11.22GlobeNewswireMoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

26.09.22GlobeNewswireMoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

26.07.22GlobeNewswireMoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

12.05.22GlobeNewswireMoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics News

MoonLake Immunotherapeutics News: auf dieser Seite finden Sie alle MoonLake Immunotherapeutics News und Nachrichten zur MoonLake Immunotherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch MoonLake Immunotherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um MoonLake Immunotherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.